Why the study?
The indication for systemic thrombolytic therapy in intermediate-risk pulmonary embolism remains controversial, with conflicting recommendations among authors and major professional guidelines.
Does systemic thrombolytic therapy reduce mortality or hemodynamic deterioration compared to anticoagulation therapy in patients with intermediate-risk pulmonary embolism?
Systematic Review (n=39,879)
Does systemic thrombolytic therapy reduce mortality or hemodynamic deterioration compared to anticoagulation therapy in patients with intermediate-risk pulmonary embolism?
In patients with intermediate-risk pulmonary embolism, systemic thrombolysis reduces hemodynamic deterioration compared to anticoagulation but does not improve mortality and carries a nearly 10% risk of major bleeding.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ramírez et al. (2024) conducted a systematic review in Acute intermediate-risk pulmonary embolism (n=39,879). Systemic thrombolysis vs. Anticoagulation alone was evaluated on Early mortality (OR 0.6, 95% CI 0.34-1.06).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: